替罗非班用于治疗颅内动脉瘤栓塞期间的血栓栓塞的临床疗效观察

旨在评价替罗非班用于治疗颅内动脉瘤血栓栓塞的临床疗效和安全性。选取289例经颅内动脉瘤采用微弹簧圈栓塞治疗后发生血栓栓塞76个患者,其中48个进行替罗非班治疗和28个阿司匹林治疗。结果显示,与阿司匹林治疗患者比较,用药治疗1天、3个月、6个月,替罗非班用药患者血栓栓塞完全或部分溶解率显著增高,分别为(10.71% vs 66.67%),(21.43% vs 83.33%),(55.56% vs 95.83%)。结果表明,替罗非班能有效地解决血栓栓塞症,并且具有较高的安全性和再通率。

Clinical efficacy and safety of tirofiban in the treatment of thromboembolism during intracranial aneurysm embolization

To evaluate the clinical efficacy and safety of tirofiban in the treatment of thromboembolism, 76 cases of thromboembolism found in 289 cases of intracranial aneurysms whom were treated with microcoil embolization were treated with tirofiban(48 cases) and aspirin (28 cases). Results show, compared to the aspirin treatment group, the rate of thromboembolism completely or partially dissolved in the tirofiban treatment group at the day 1,3 months, 6 months follow-up were significant increased(10.71% vs 66.67%),(21.43% vs 83.33%),(55.56% vs 95.83%), respectively. These results indicate that tirofiban can effectively resolve thromboembolism,and has a high safety and recanalization rate.